Skip to main content
Premium Trial:

Request an Annual Quote

Caribou Biosciences Raises $30M in Series B Funding

NEW YORK (GenomeWeb) – Caribou Biosciences, a CRISPR platform technology firm, has completed a $30 million Series B financing round.

New investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech joined existing investors in the round, including F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures.

The proceeds will go towards platform technology development and applications in agriculture, therapeutics, biological research, and industrial biotechnology, Caribou CEO Rachel Haurwitz said in a statement. She added that the investors provide "further validation of the potential" for the firm's CRISPR technology.

Caribou added Anterra Capital's Philip Austin to its Board of Directors.

The financing follows the completion of an initial public offering that raised $112.9 million for Intellia Therapeutics, the pharmaceuticals arm of Caribou. Novartis has also invested heavily in Intellia and is collaborating with the therapeutics firm on CRISPR-based treatments.